» Articles » PMID: 38887633

Challenges in Diagnosing and Managing the Spectrum of Primary Aldosteronism

Overview
Journal J Endocr Soc
Specialty Endocrinology
Date 2024 Jun 18
PMID 38887633
Authors
Affiliations
Soon will be listed here.
Abstract

Primary aldosteronism, characterized by the dysregulated production of aldosterone from 1 or both adrenal glands, is the most common endocrine cause of hypertension. It confers a high risk of cardiovascular, renal, and metabolic complications that can be ameliorated with targeted medical therapy or surgery. Diagnosis can be achieved with a positive screening test (elevated aldosterone to renin ratio) followed by confirmatory testing (saline, captopril, fludrocortisone, or oral salt challenges) and subtyping (adrenal imaging and adrenal vein sampling). However, the diagnostic pathway may be complicated by interfering medications, intraindividual variations, and concurrent autonomous cortisol secretion. Furthermore, once diagnosed, careful follow-up is needed to ensure that treatment targets are reached and adverse effects, or even recurrence, are promptly addressed. These challenges will be illustrated in a series of case studies drawn from our endocrine hypertension clinic. We will offer guidance on strategies to facilitate an accurate and timely diagnosis of primary aldosteronism together with a discussion of treatment targets which should be achieved for optimal patient outcomes.

References
1.
Turcu A, Yang J, Vaidya A . Primary aldosteronism - a multidimensional syndrome. Nat Rev Endocrinol. 2022; 18(11):665-682. DOI: 10.1038/s41574-022-00730-2. View

2.
Bakris G, Yang Y, McCabe J, Liu J, Tan X, Benn V . Efficacy and Safety of Ocedurenone: Subgroup Analysis of the BLOCK-CKD Study. Am J Hypertens. 2023; 36(11):612-618. PMC: 10570658. DOI: 10.1093/ajh/hpad066. View

3.
Cameron N, Blyler C, Bello N . Oral Contraceptive Pills and Hypertension: A Review of Current Evidence and Recommendations. Hypertension. 2023; 80(5):924-935. PMC: 10852998. DOI: 10.1161/HYPERTENSIONAHA.122.20018. View

4.
Baudrand R, Guarda F, Fardella C, Hundemer G, Brown J, Williams G . Continuum of Renin-Independent Aldosteronism in Normotension. Hypertension. 2017; 69(5):950-956. PMC: 5391287. DOI: 10.1161/HYPERTENSIONAHA.116.08952. View

5.
Rose L, UNDERWOOD R, Newmark S, Kisch E, Williams G . Pathophysiology of spironolactone-induced gynecomastia. Ann Intern Med. 1977; 87(4):398-403. DOI: 10.7326/0003-4819-87-4-398. View